BIM
RPRX icon

Barton Investment Management’s Royalty Pharma RPRX Stock Holding History

Barton Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
30,046
+11,171
+59% +$581K 0.23% 27
2026
Q1 		$905K Buy
+18,875
New +$827K 0.11% 33

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barton Investment Management's RPRX Position: Q2 2026 in Review

Barton Investment Management increased its Royalty Pharma (RPRX) stake by 59% in Q2 2026, buying an estimated $581K and bringing the position to 30,046 shares worth $1.68M. The position accounts for 0.23% of the portfolio, ranked #27.

Barton Investment Management first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Barton Investment Management held 30,046 shares of Royalty Pharma worth $1.68M as of Q2 2026.
  • Barton Investment Management bought 11,171 Royalty Pharma shares in Q2 2026, an estimated $581K.
  • Royalty Pharma made up 0.23% of Barton Investment Management's portfolio in Q2 2026, its #27 holding.
  • Barton Investment Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Barton Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.